Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Germany
Charité Research Organization gmbh, Berlin Fraunhofer Institute For Translational Medicine And Pharmacology, Berlin